glp 1 agonist effects GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes Glucagon-Like Peptide-1: New Regulator in

Keywords: Pregnant Women, Safety, Diabetes in pregnancy, Obesity STRENGTHS AND LIMITATIONS OF THIS STUDY

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as highly effective therapies for weight reduction and glycemic control, and they show promise in improving fertility outcomes in women with obesity and PCOS [5,6]

GLP-1RAs promote weight loss by reducing appetite via slowed gastric emptying and acting on the brains appetite centres

However, the reduction in HbA1c was non-significantly diminished with exenatide twice-daily in the small subset of patients (5%) with higher titers

GLP-1 increased cAMP but did not affect amylase secretion

We compared the use of GLP-1RAs with second- or third-line glucose-lowering therapy to minimise confounding [22], thereby allowing us to explore the impact of including a reference group with the same disease stage, even though we adjusted for microvascular complications